Physician profile
Laura E O Hern
NPI 1346556511
$6,893.93
in general payments reported to CMS, 2019-2025
35 companies · $1,989 in 2025
The $1,989 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $874 · 2022: $1,242 · 2023: $1,368 · 2024: $1,421 · 2025: $1,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,758 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,757.59 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $641.06 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $611.57 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $504.16 | 2021-2025 | |
| Insulet Corporation | $444.57 | 2021-2025 | Omnipod |
| Abbott Laboratories | $426.91 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $407.56 | 2021-2025 | Evenity, Prolia, Tepezza |
| Dexcom, INC. | $389.17 | 2021-2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $379.27 | 2024-2025 | Cequr Simplicity |
| Novo Nordisk INC | $373.04 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $325.85 | 2021-2025 | |
| Corcept Therapeutics | $308.20 | 2023-2025 | Korlym |
| Tandem Diabetes Care, INC. | $264.43 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $249.09 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $231.86 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Beta Bionics, INC. | $167.24 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $147.81 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.42 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $134.60 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2022 | |
| Horizon Therapeutics Plc | $98.32 | 2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $87.07 | 2025 | Yorvipath, Skytrofa |
| Radius Health, INC. | $54.82 | 2022 | |
| Averitas Pharma INC. | $54.22 | 2024-2025 | Qutenza |
| Nevro Corp. | $43.33 | 2023-2024 | Senza |
| Antares Pharma, INC. | $39.63 | 2024 | Xyosted |
| Rhythm Pharmaceuticals, INC. | $39.13 | 2025 | Imcivree |
| Recordati_rare_diseases_inc. | $38.39 | 2023-2025 | Isturisa, Signifor Lar |
| Kyowa Kirin, INC. | $27.46 | 2024 | Crysvita |
| Merck Sharp & Dohme LLC | $22.67 | 2023 | Steglatro, Steglujan |
| Ascensia Diabetes Care US INC. | $21.57 | 2025 | |
| Mannkind Corporation | $19.68 | 2023 | Afrezza |
| Halozyme INC | $19.66 | 2023 | |
| Soleno Therapeutics, INC. | $18.74 | 2025 | Vykat Xr |
| Chiesi USA, INC. | $15.33 | 2025 | Mycapssa |
| Alexion Pharmaceuticals, INC. | $15.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura O Hern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.